Clinical Report: Identifying Cardiovascular Biomarkers in Dermal Interstitial Fluid
Overview
This review discusses the potential of dermal interstitial fluid (ISF) for continuous cardiovascular biomarker monitoring, highlighting advances in biosensing technologies. While proof-of-concept studies show promise, clinical translation remains limited.
Background
Cardiovascular disease (CVD) is the leading cause of mortality globally, with early detection being crucial for effective management. Traditional blood sampling methods have limitations, particularly in patients with indeterminate troponin levels, leading to prolonged observation. Continuous monitoring of biomarkers in dermal ISF could provide timely data.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
Dermal interstitial fluid (ISF) offers a minimally invasive alternative for continuous biomarker monitoring.
Current biosensing technologies include microneedle arrays, hydrogel implants, and electrokinetic extraction methods.
Key cardiovascular biomarkers such as troponin, natriuretic peptides, CRP, and microRNAs can potentially be monitored via ISF.
Early studies demonstrate proof-of-concept for ISF-based detection.
Challenges include clinical workflow integration, data interpretation, and regulatory oversight.
Clinical Implications
Successful implementation of continuous dermal monitoring will require addressing integration and interpretation challenges within clinical settings.
Conclusion
Dermal ISF monitoring represents an advancement in cardiovascular diagnostics. Continued research is essential for overcoming current limitations.
